Perspective Therapeutics (CATX) vs Cellectis S.A. (CLLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Perspective Therapeutics (CATX) has outperformed Cellectis S.A. (CLLS) over the past year, losing 63.9% versus a loss of 80.4%. Over five years, CATX leads with a -84.6% price change compared with -89.4% for CLLS. Cellectis S.A. is the larger company by market cap ($92.8 million vs $91.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | CLLS |
|---|---|---|
| Share price | $0.7538 | $0.9209 |
| Market cap | $91.03M | $92.76M |
| 1-day change | -3.85% | -7.89% |
| YTD return | -72.59% | -80.97% |
| 1-year return | -63.93% | -80.36% |
| 5-year return | -84.62% | -89.40% |
| EPS (TTM) | $-1.25 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $72.95M |
| Revenue growth (YoY) | — | +75.76% |
| Net income (latest FY) | $-103.12M | $-67.59M |
| Gross margin | — | 100.00% |
| Operating margin | — | -45.34% |
| Net margin | — | -92.66% |
| 52-week high | $6.16 | $5.45 |
| 52-week low | $0.73 | $0.881 |
| Distance from 52-week high | -87.76% | -83.10% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +1188.14% | +497.24% |
| Average volume | 2.70M | 115.00K |
| Shares outstanding | 120.76M | 72.73M |
| Employees | 163 | 224 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CATX has outperformed CLLS by 16.4 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
CATX vs CLLS FAQ
Which is bigger, Perspective Therapeutics or Cellectis S.A.?
Cellectis S.A. (CLLS) is larger, with a market capitalization of $92.76M compared with $91.03M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or CLLS?
CATX returned -63.93% over the past 12 months, compared with -80.36% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Cellectis S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.